Susquehanna International Group, LLP Nurix Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$18.93 - $25.69 $577,365 - $783,545	30,500 Added 97.76%	61,700 $1.39 Million
Q2 2024 Aug 15, 2024	BUY	$12.02 - $21.3 $25,242 - $44,730	2,100 Added 7.22%	31,200 $651,000
Q1 2024 May 07, 2024	BUY	$7.77 - $15.66 $79,254 - $159,732	10,200 Added 53.97%	29,100 $427,000
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $80,325 - $202,419	18,900 New	18,900 $195,000
Q2 2023 Aug 11, 2023	BUY	$8.7 - $13.28 $36,540 - $55,776	4,200 Added 4.71%	93,300 $932,000
Q1 2023 May 16, 2023	BUY	$8.56 - $13.26 $623,168 - $965,328	72,800 Added 446.63%	89,100 $791,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $348,058 - $515,027	-35,300 Reduced 68.41%	16,300 $178,000
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $48,087 - $77,259	-3,900 Reduced 7.03%	51,600 $672,000
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $7,092 - $13,338	-900 Reduced 1.6%	55,500 $703,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $729,816 - $1.67 Million	56,400 New	56,400 $790,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.